Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Is Meloxicam recalled?

Yes — there is an active recall. 1 ongoing FDA recall mention Meloxicam (9 total). Check the affected lots below.

Most common reason: Cross-contamination (2 of these recalls)

Recalls are matched by product description. A recall usually affects specific lots, not every package of Meloxicam. “Active” means an FDA recall is still ongoing; “closed” means it was terminated or completed. Checked against openFDA on Oct 10, 2026.

Meloxicam recalls on record

none so far in 2026; 9 on record, newest first
Class III · Low risk

Zynrelef (bupivacaine and meloxicam)

Defective Delivery System: An incorrect 10 mL (12 mL) Luer (slip) syringe packaged in one lot of Zynrelef 400 mg/12 mg kit

Terminated Packaging defect Heron Therapeutics, INC. NDC 47426-301-02 D-1335-2022
Class II · Moderate risk

Meloxicam Tablets

CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.

Terminated Temperature excursion Cardinal Healthcare D-0190-2024
Class II · Moderate risk

Meloxicam Tablets

CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Terminated Temperature excursion Cardinal Health Inc. NDC 69097-158-07 D-0463-2021
Class III · Low risk

Mobic (meloxicam)

Labeling: Incorrect or missing package insert. One lot of Mobic Tablets is packaged with an incorrect insert.

Terminated Labeling / mix-up Boehringer Ingelheim Pharmaceuticals, Inc. NDC 0597-0030-01 D-0007-2018
Class II · Moderate risk

All lidocaine

Lack of Processing Controls

Terminated cGMP deviation Reliable Rexall-A Compounding Pharmacy D-1103-2016
Class II · Moderate risk

Meloxicam capsules

Penicillin Cross Contamination: Multiple finished products potentially contaminated with penicillin.

Terminated Cross-contamination South Coast Specialty Compounding, Inc. D-1339-2015
Class II · Moderate risk

Meloxicam active pharmaceutical ingredient packaged in varying…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-776-2015
Class II · Moderate risk

Meloxicam 5 mg/ml Injection

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Ongoing Sterility / contamination Lowlite Investments, Inc. D/B/A Olympia Pharmacy D-752-2013
Class II · Moderate risk

Meloxicam Tablets

Tablet Thickness: Recall was initiated due to the presence of one slightly oversized tablet in a bottle of the identified lot.

Terminated Failed specification Apotex Corp. NDC 60505-3579-1 D-1443-2012